At a glance
CRO demand, Q3 2026
Exhibit 1CRO book-to-bill, Q3 2026
New net awards divided by revenue; above 1.0 means backlog is growing
The category on a page
Exhibit 2Where clinical research sits
Profit impact against supply risk, R&D subcategories
Typical savings vs unmanaged award
Base contract plus change orders and pass-throughs
Value levers
In order of value.
Fixed assumptions, a change-order rate card and a cap on unapproved changes.
Benchmark investigator grants; pay pass-throughs at cost with receipts.
FSP for resource control; full service for turnkey studies.
Price per patient, site and visit instead of FTE hours.
Credits for missed enrolment, data and database-lock dates.
Ask for AI-driven efficiency to show in monitoring and data-management units.
How to buy it
KPIs to track
For the monthly review
Where most buyers are, and what good looks like
| Most buyers today | Best practice | ||
|---|---|---|---|
| Model | Study-by-study award | → | Panel with FSP and full-service mix |
| Pricing | FTE hours | → | Unit-based with benchmarks |
| Changes | Approved after the fact | → | Rate card and pre-approval |
| Pass-throughs | Invoice as billed | → | At cost, reconciled monthly |
| Performance | Reports only | → | KPIs with credits |
What AI changes
More in the AI disruption tab.
From the category playbook
Clinical research (CRO)
| Positioning | Pivotal full-service trials & strategic partnerships - Strategic · FSP & niche labs - Leverage |
| Recommended route | Strategic CRO partnership(s) for core programmes; FSP for scalable functions; competitive bids per study |
| Spec approach | Unit-based/outcome pricing; tight change-order governance; transparent pass-through & investigator grants; quality/timeline KPIs |
| Top value levers | 1) Operating model (FSP vs full-service) 2) Change-order & pass-through control 3) Dual-sourcing & low-cost-region trial placement |
| Key risk | Trial-cost inflation · timeline/quality risk · recruitment · change-order leakage |
| Headline KPIs | Cost per patient/site · change-orders vs baseline · enrolment rate · data quality/query rate · timeline adherence |
Exhibit 5Kraljic positioning (category playbook)
Sub-categories by profit impact and supply risk
Exhibit 6Where the money goes
Typical cost split
Exhibit 7CRO market growth to 2031 by segment
CAGR %
Savings potential (category playbook)
Typical range on addressable spend
Verified benchmarks - Global
- Global CRO market ~$87-99B in 2026, growing ~7.8%/yr to 2031; clinical-trial management is the fastest segment (~8.1% CAGR)
- IQVIA backlog ~$34B on a 1.22× book-to-bill; emerging-biopharma funding ~$35B in Q2 (2× YoY) with double-digit RFP growth - demand improving but unevenT2IQVIA Q2-Q3 2026 / BioWorld · Q3 2026
- North America ~50% of spend; Asia-Pacific fastest-growing on cost and patient pools - no public price index, priced per unit / FSP / full-serviceT4Industry (CRO statistics 2026) · 2026
Supplier landscape - Global
Top global players and the local or regional players that matter here. Illustrative, from public sources; not an endorsement.
Global players
- IQVIA / ICON plcLargest global CROs
- Fortrea / Parexel / PPD (Thermo Fisher)Top-tier full-service CROs
- Medpace / Syneos HealthFull-service CROs
- Charles River / WuXi (preclinical/labs)Preclinical & lab services
Value levers (category playbook)
CRO is a scope-and-pass-through game - the headline unit rate is a fraction of the story; the money is in change-order discipline, pass-through and investigator-grant control, and the functional-vs-full-service model, not the FTE rate.
Lock scope and govern change orders hard - CRO margin is made on changes, and unmanaged change orders routinely exceed the base award.
Benchmark and control pass-throughs and investigator/site grants separately; these are large, opaque and often un-negotiated.
Decide functional-service-provider vs full-service by trial type; FSP gives rate and resource control, full-service gives convenience at a premium.
Move to transparent unit/activity-based pricing (per patient, per site, per monitoring visit) with benchmarks; FTE-based pricing hides utilisation.
Contract enrolment, data-quality and timeline KPIs with credits; CRO underperformance delays the trial, which dwarfs any sourcing saving.
Make AI do the work
AI and decentralised-trial tech are changing CRO economics - AI in site selection, patient recruitment and data cleaning cuts cost and timelines. Demand that providers deploy it and share the saving, and watch for 'AI-enabled' premium pricing on what's becoming table stakes. In a category where speed-to-data is the real value, the AI question is timeline compression, not just rate.
Reactive vs proactive (category playbook)
| Reactive | Proactive | ||
|---|---|---|---|
| Model | Full-service fixed bid | → | Unit-based + FSP mix; cap change orders |
| Scope | Accept change orders | → | Tight scope + change-order governance |
| Sourcing | Single preferred CRO | → | Dual-CRO / FSP for leverage & continuity |
| Sites | CRO-selected sites | → | Data-driven site & country selection |
| Oversight | Trust CRO reporting | → | Risk-based monitoring + your own KRIs |
How AI is changing the category
- AI accelerates patient recruitment, site selection and protocol design - cutting timelines and cost.
- Risk-based monitoring + AI reduces costly on-site CRA effort.
- AI data management/query automation and synthetic control arms lower study cost.
- AI estimation tools expose padded bids and change-order patterns.
What to do about it
- Reward CROs that use AI recruitment/RBM with timeline- and cost-linked terms.
- Benchmark bids and change-orders with AI; insist on unit/outcome pricing.
- Explore AI/synthetic-control and decentralised-trial designs to cut patient cost.
- Place trials in cost-effective regions and dual-source to keep leverage.
Each number carries source, as-of date and a credibility tier (T1 official · T2 index/survey · T3 analyst · T4 estimate). Figures are market-size/growth forecasts (Mordor/Fortune) and IQVIA bookings data - no public price index exists, so studies are priced per unit/protocol (FSP/full-service). Demand is improving but uneven; control change-orders and pass-throughs, reward AI-enabled recruitment/RBM, and place trials by cost and patient access.
Full written analysis
Written live for Clinical research (CRO) and your region, grounded on the figures above. Public data only.
Written live for this category and region when the page opens in a browser.
Negotiation playbook
Negotiation playbook
Demand has recovered, so CROs have more pricing power for 2027. Your leverage is study volume, multi-year commitments and control of scope.
Pick the right commercial model
| Unit-based full serviceUsual best | Price per patient, site and visit; best visibility. |
| FSP (functional) | Rate per role; you manage the work. |
| FTE / time and materials | Simple but hides utilisation. |
| Risk-share on milestones | Fees tied to enrolment or database lock. |
Questions to ask suppliers
- Change orders
Will you agree a change-order rate card now, and cap unapproved changes at a fixed share of the budget?
Good answer: rate card and cap. - Pass-throughs
Will you bill pass-throughs and investigator grants at cost, with monthly reconciliation and no handling fee?
Good answer: at cost with receipts. - Enrolment
What enrolment dates will you commit to by country, and what credit applies if you miss them?
Good answer: credits if late. - AI productivity
Which units get cheaper because of your AI tools, and by how much versus last year's pricing?
Good answer: visible in price. - Team stability
Will you name the project lead and keep turnover of key roles below an agreed level?
Good answer: named leads. - Data and exit
If we move the study, how fast will you transfer all data and documents, and at what cost?
Good answer: full transfer.
Your leverage
- Portfolio volume
- Multi-study commitments
- Therapeutic area repeat work
- Second-source FSP
Watch out for
- Low base price recovered through change orders
- Pass-through mark-ups
- 'AI-enabled' premiums
- Overstated backlog commitments
CRO - 2026 market & pricing signals
| Component | Change / forecast | Source |
|---|---|---|
| CRO market growth (to 2031) | ~+7.8% CAGR | T3Industry forecasts · 2026 |
| Clinical-trial mgmt segment | ~+8.1% CAGR | T3Mordor Intelligence · 2026 |
| IQVIA book-to-bill | 1.22× | T2IQVIA · Q2 2026 |
| Pricing model | Per-unit / FSP | T4No public index · 2026 |
Pricing models (category playbook)
CRO pricing is unit-of-work driven and change-order heavy - lock the model and control scope creep, which is where margin hides.
| Unit-based / fee-for-serviceUsual best | Price per unit (site, patient, monitoring visit) - transparent and benchmarkable against change orders. |
| Full-service fixed bid | One number for the trial - convenient, but change orders erode it; cap them up front. |
| FSP (functional, resource-based) | Buy functions (monitoring, data mgmt) as flexible capacity - cheaper for repeatable work. |
| Risk-share / milestone | Payment tied to enrolment or milestones - aligns the CRO on timelines. |
Benchmarks to bring to the table - Global
- Global CRO market ~$87-99B in 2026, growing ~7.8%/yr to 2031; clinical-trial management is the fastest segment (~8.1% CAGR)
- IQVIA backlog ~$34B on a 1.22× book-to-bill; emerging-biopharma funding ~$35B in Q2 (2× YoY) with double-digit RFP growth - demand improving but unevenT2IQVIA Q2-Q3 2026 / BioWorld · Q3 2026
- North America ~50% of spend; Asia-Pacific fastest-growing on cost and patient pools - no public price index, priced per unit / FSP / full-serviceT4Industry (CRO statistics 2026) · 2026
AI disruption
Tailwinds for buyers
- AI site selection finds patients faster.
- AI data cleaning reduces monitoring and data-management hours.
- AI drafting of protocols and reports.
- Decentralised trial tools cut site visits.
- AI safety signal detection.
- Better feasibility forecasts reduce re-work.
Headwinds for buyers
- CROs price AI tools as a premium.
- Data lock-in on CRO platforms.
- Change orders absorb efficiency gains.
- Regulators still require human oversight.
- Validation burden for AI used in trials.
- Data privacy across countries.
How to capture it
Ask each CRO which unit costs fall with AI and write those reductions into the rate card.
Who is changing the market
- More than 400 AI agents deployed across its operations
- Says AI was a clear differentiator in Q3 clinical wins
- Says customers choose it for AI-driven productivity and speed
- Record bookings while cutting cost
- Unified trial data and AI tools used by sponsors and CROs
- Lets sponsors run more work in-house or with smaller CROs
Category playbook view
Tailwinds
- AI site selection and patient recruitment cut the slowest, costliest part of a trial - speed-to-data is the real value.
- AI data cleaning and monitoring reduce the FTE and pass-through load.
- Decentralised-trial tech shrinks site and monitoring cost.
Headwinds
- CROs price 'AI-enabled' delivery as a premium for capability fast becoming table stakes.
- Change orders absorb AI savings unless scope is locked - the margin is made on changes.
- Platform and data lock-in grows as the CRO's AI holds your trial data.
Capture it
Timeline is the value here - contract for AI-driven speed and make the CRO share it, don't pay a premium for standardising automation, and lock scope so change orders don't eat the saving.
Risk radar
Risk radar
Exposure by dimension, 0-100, Global
Risk heat matrix
Impact against likelihood, category playbook; register numbers follow
- Regulatory/GCP quality
- Patient-data privacy
- Timeline/enrolment
- Concentration/lock-in
Top risk flags
- HighRegulatory & GCP / clinical-trial quality
- HighPatient-data privacy & ethics
- HighTimeline / enrolment failure
- MediumVendor concentration & lock-in
Risk register
US list of biotech companies of concern due by 18 Dec 2026.
Book-to-bill 1.1-1.6x across the big CROs.
Low bids recovered through changes.
Delay costs far exceed price savings.
IQVIA cut $2.1bn of inactive trials from backlog.
Patient data across many countries.
Market pulse
What the biggest suppliers are reporting
From their latest results and investor material.
Q3 2026. Book-to-bill 1.2x; strongest clinical bookings since 2022; backlog $32.6bn after a $2.1bn clean-up of inactive trials; 400+ AI agents deployed.
Q3 2026. Record net awards, but revenue -2.9% YoY; backlog $24.5bn; mid-single-digit 2027 growth described as possible.
Q3 2026. Record awards $873m (+10.6%), book-to-bill about 1.22x; EBITDA margin 24%; backlog $3.2bn.
Q3 2026. Preclinical (DSA) book-to-bill 1.09x, fourth quarter above 1x; backlog $2.03bn; modest cut in discounting on new proposals.
Q2 FY27. +13% vs Q1; EBITDA margin 18% vs 22% a year ago; first deal at its US Bayview biologics site; FY27 revenue to fall single digits.
Q3 2026. Lab products and biopharma services +15% (10% organic); Life Sciences Solutions +1% organic; China up low double digits; FY organic guide 4%.
Latest developments
Dated, newest first. Checked 16 Nov 2026.
Preclinical book-to-bill 1.09x, fourth quarter above 1x.
So what: Preclinical capacity is tightening; book 2027 slots early.
Charles River Q3 2026 results (8-K) →$3.2bn, +15%; backlog cut $2.1bn for inactive trials.
So what: Expect firmer pricing on new full-service awards.
IQVIA Q3 2026 results (8-K) →Fourth quarter in a row above 1.3x.
So what: ICON needs to convert bookings; negotiate now.
ICON plc →Book-to-bill about 1.22x; margin 24%.
So what: Mid-size biotech CRO capacity is filling.
Medpace Q3 2026 results (8-K) →What this means for your next negotiation
- Demand has recovered across the big CROs; 2027 awards will be priced higher unless you lock terms now.
- Make change orders and pass-throughs the centre of the negotiation, not the headline rate.
- Ask how AI lowers each unit cost and write it into the rate card.
Signals to watch next quarter
May restrict Chinese labs used by CROs.
Shows pricing power for the year.
Could speed multinational trial approvals.
Curated developments (category tool)
IQVIA Q3 2026 results →
IQVIA →
Industry forecasts / IQVIA
IQVIA / BioWorld
Category note
Benchmarks and forecasts - Global
- Global CRO market ~$87-99B in 2026, growing ~7.8%/yr to 2031; clinical-trial management is the fastest segment (~8.1% CAGR)
- IQVIA backlog ~$34B on a 1.22× book-to-bill; emerging-biopharma funding ~$35B in Q2 (2× YoY) with double-digit RFP growth - demand improving but unevenT2IQVIA Q2-Q3 2026 / BioWorld · Q3 2026
- North America ~50% of spend; Asia-Pacific fastest-growing on cost and patient pools - no public price index, priced per unit / FSP / full-serviceT4Industry (CRO statistics 2026) · 2026
Sources
- IQVIA Q3 2026 results (8-K) · 27 Oct 2026
- ICON Q3 2026 results · 27 Oct 2026
- Medpace Q3 2026 results (8-K) · 21 Oct 2026
- Charles River Q3 2026 results (8-K) · 4 Nov 2026
- Syngene Q2 FY27 (Medical Dialogues) · Nov 2026
- European Commission, Biotech Act update · Jun 2026
- SFDA news · Jan 2026
Figures checked 16 Nov 2026. Tags: Official = published by the source; Derived = calculated from published figures; Judgement = The Procurement Lens view.